WillItSurvive
Pharma and healthcare groups · United States

DaVita

davita.com ↗

DaVita runs outpatient dialysis clinics across the US, treating kidney failure patients daily.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from Fall 2026 · Every call on the record Checkpoint: CMS finalizes CY2027 ESRD payment rule (proposed base rate $299.55)
The call

DaVita and Fresenius split the US dialysis market between them, with regulation and Medicare economics doing more to shape the business than any software could.

DaVita operates dialysis clinics where people with kidney failure go for life-sustaining treatment multiple times per week. The company is very hard to replace because it owns thousands of physical clinics across the country, has licenses that took years to get, and has long-standing deals with Medicare (the government health program for seniors) that pay for most of its patients. DaVita and its main rival Fresenius together control almost three-quarters of the U.S. market. The thing that could change everything is an antitrust case brought by the Federal Trade Commission and a lawsuit from unions claiming the two companies have kept prices artificially high instead of competing fairly. If courts force them to actually compete or break apart, DaVita's advantage would shrink quickly.

Why
01
AI pressure: None apparent. AI tools like DaVita's own PD Loss Model help retain home dialysis patients; no AI system can replace the clinic or the needle. Could AI do the core job? Unlikely.
02
Bigger players: Fresenius Medical Care. Fresenius runs the other half of the US dialysis duopoly (~34% share) with its own clinic network, but neither side is taking share from the other. Could a giant copy it? No, they are blocked.
03
What protects it. Physical clinic licensure, Medicare reimbursement relationships, and a two-player market structure that new entrants cannot easily replicate.
What would change this call
FTC antitrust probe into DaVita/Fresenius non-compete contracts reaches a decision or consent order. Would show whether regulators can force structural changes to the dialysis duopoly.
UFCW Local 1776 price-fixing class action against DaVita and Fresenius reaches ruling or settlement in Colorado federal court. Would show whether courts find evidence of coordinated pricing between the two dominant players.
CMS finalizes CY2027 ESRD payment rate in late 2026. Would show whether Medicare reimbursement, 68% of DaVita's revenue, is rising or being squeezed.
Key numbers
  • 2,657 US clinics, ~200,500 patients (2025-12-31)
  • $13.653B FY2025 revenue, $1.078B net income (2025-12-31)
  • 68% revenue from Medicare, 32% commercial drives profit (2025-12-31)
Named risks
  • FTC antitrust investigation into DaVita-Fresenius duopoly opened 2024, ongoing into 2026. Severity: high
  • Private price-fixing class action UFCW Local 1776 v. DaVita and Fresenius active in Colorado federal court as of Oct 2025. Severity: high
  • CMS reimbursement rate changes could compress margins if future rules turn unfavorable. Severity: medium
  • Repeat compliance exposure shown by $34.5M False Claims Act settlement in July 2024. Severity: medium
  • Berkshire Hathaway incrementally trimming its stake could pressure investor sentiment. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Fresenius Medical CarecontestingDaVita ~38% vs Fresenius ~34% U.S. dialysis share as of 2025, per March 2026 market report
UnitedHealth/Optumgaining onOptum increasingly active in value-based kidney care, flagged as watch item, not yet active share erosion as of 2026
Vantive (Baxter renal spinoff)contestingPartnering with U.S. Renal Care for digital peritoneal dialysis expansion, Oct 2025
U.S. Renal CarecontestingMid-size chain competing in U.S. dialysis market as of March 2026 market report
Questions people ask
Is DaVita profitable in 2026?
Yes. DaVita reported Q1 2026 (quarter ended March 31, 2026) consolidated revenue of $3.416 billion, operating income of $482 million, and diluted EPS of $2.87, beating consensus estimates of $2.33 EPS, with revenue up about 6.0% year over year, per its May 5, 2026 earnings release.
Could AI replace DaVita's dialysis clinics?
No. Dialysis requires physical machines, licensed clinics, and clinicians who assume clinical liability, none of which AI can substitute. DaVita uses AI internally, e.g. its PD Loss Model flags at-risk home dialysis patients and reportedly cut return-to-in-center rates by 15% as of April 2026, but this is an efficiency layer, not a replacement for the service itself.
Who is DaVita's biggest competitor?
Fresenius Medical Care of Germany, which holds roughly 34% U.S. dialysis market share versus DaVita's roughly 38% as of 2025, per a March 2026 GMI Insights market report. Together the two firms have historically controlled about 77% of U.S. dialysis centers, forming what analysts call a duopoly.
Who owns DaVita?
DaVita is a publicly traded company (NYSE: DVA) with Berkshire Hathaway as its largest shareholder. Berkshire has held a stake since Q4 2011 and trimmed its position on May 1, 2026, selling about 1.22 million shares worth roughly $182.8 million, leaving it with 28,880,209 shares.
Is DaVita facing legal or regulatory trouble in 2026?
Yes. DaVita faces an ongoing FTC antitrust investigation opened in 2024 and a private price-fixing class action, UFCW Local 1776 v. DaVita and Fresenius, with an active docket in Colorado federal court as of October 30, 2025. DaVita also paid a $34.5 million False Claims Act settlement over kickback allegations in July 2024.
How does DaVita make money given Medicare pays most of its bills?
As of fiscal year 2025, 68% of DaVita's revenue came from Medicare and government programs, but the remaining 32% from commercial insurers generates nearly all of its profit due to higher commercial reimbursement rates, per DaVita's FY2025 financials showing $13.653 billion in revenue and $1.078 billion in net income.
Timeline
  • 2026-07-20DaVita stock trades near 52-week highs at approximately $236 per share
  • 2026-06-24CMS issues CY2027 proposed rule raising ESRD PPS base rate to $299.55 per treatment
  • 2026-05-05DaVita reports Q1 2026 results: $3.416B revenue, $482M operating income, $2.87 EPS, beats estimates
  • 2026-05-01Berkshire Hathaway sells ~1.22 million DaVita shares worth ~$182.8 million
  • 2026-04-13DaVita's PD Loss Model reported to cut return-to-in-center dialysis rates by 15%
  • 2025-11-20CMS finalizes CY2026 ESRD PPS rule, raising base rate 2.9% to $281.71 per treatment
  • 2025-10-30UFCW Local 1776 price-fixing class action against DaVita and Fresenius remains active in Colorado federal court
  • 2024-07-18DaVita pays over $34.5 million to settle False Claims Act kickback allegations
  • 2024FTC opens antitrust investigation into DaVita and Fresenius dialysis duopoly
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources